The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.
The European Commission has approved a fixed dose combination of Roche’s antibody blockbusters Herceptin and Perjeta under the new brand name Phesgo. ... In Roche’s half-year report for 2020, sales of Herceptin had dropped by 28%, reflecting the
Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA
It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.
Last year, sales of Herceptin were flat overall at around $7bn, but fell 16% in Europe and Japan as biosimilars started to gather momentum. ... Perjeta has been growing strongly – rising a third to $2.8bn last year – thanks to data showing it
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...